What Is Amdocs's (NASDAQ:DOX) P/E Ratio After Its Share Price Rocketed?

Those holding Amdocs (NASDAQ:DOX) shares must be pleased that the share price has rebounded 36% in the last thirty days. But unfortunately, the stock is still down by 15% over a quarter. And the full year gain of 17% isn't too shabby, either!

All else being equal, a sharp share price increase should make a stock less attractive to potential investors. While the market sentiment towards a stock is very changeable, in the long run, the share price will tend to move in the same direction as earnings per share. The implication here is that deep value investors might steer clear when expectations of a company are too high. One way to gauge market expectations of a stock is to look at its Price to Earnings Ratio (PE Ratio). A high P/E ratio means that investors have a high expectation about future growth, while a low P/E ratio means they have low expectations about future growth.

Check out our latest analysis for Amdocs

Does Amdocs Have A Relatively High Or Low P/E For Its Industry?

We can tell from its P/E ratio of 17.39 that sentiment around Amdocs isn't particularly high. We can see in the image below that the average P/E (26.5) for companies in the it industry is higher than Amdocs's P/E.

Amdocs's P/E tells us that market participants think it will not fare as well as its peers in the same industry. Many investors like to buy stocks when the market is pessimistic about their prospects. You should delve deeper. I like to check if company insiders have been buying or selling.

How Growth Rates Impact P/E Ratios

Generally speaking the rate of earnings growth has a profound impact on a company's P/E multiple. If earnings are growing quickly, then the 'E' in the equation will increase faster than it would otherwise. Therefore, even if you pay a high multiple of earnings now, that multiple will become lower in the future. Then, a lower P/E should attract more buyers, pushing the share price up.

In the last year, Amdocs grew EPS like Taylor Swift grew her fan base back in 2010; the 51% gain was both fast and well deserved. Having said that, if we look back three years, EPS growth has averaged a comparatively less impressive 9.8%.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

The 'Price' in P/E reflects the market capitalization of the company. In other words, it does not consider any debt or cash that the company may have on the balance sheet. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

How Does Amdocs's Debt Impact Its P/E Ratio?

The extra options and safety that comes with Amdocs's US$486m net cash position means that it deserves a higher P/E than it would if it had a lot of net debt.

The Bottom Line On Amdocs's P/E Ratio

Amdocs's P/E is 17.4 which is above average (13.6) in its market. Its net cash position is the cherry on top of its superb EPS growth. To us, this is the sort of company that we would expect to carry an above average price tag (relative to earnings). What is very clear is that the market has become more optimistic about Amdocs over the last month, with the P/E ratio rising from 12.8 back then to 17.4 today. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is 'blood in the streets', then you may feel the opportunity has passed.

Investors should be looking to buy stocks that the market is wrong about. As value investor Benjamin Graham famously said, 'In the short run, the market is a voting machine but in the long run, it is a weighing machine. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

But note: Amdocs may not be the best stock to buy. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.